PTC Logo



We are gearing up for our most impactful year yet! Register now for #PTC2018 and fund innovative cancer research at Siteman Cancer Center and Siteman Kids at St. Louis Children’s Hospital. You have a #cancercuringbike – it’s time to ride!


* Registration fee is $100 until May 1. No discount code is required. After May 1, registration fee increases to $125.



When you refer a first-time rider or spinner, and they register and put your name in the “Referred by” field, both you and your friend will receive a $50 credit towards your fundraising! Learn more.

*Referring rider must be registered first to receive the credit. Credits are non-transferrable.

Important Dates

– May 1: Registration rates increase
– May 22: Pedal Night at the Ballpark | BUY TICKETS
– June 16: PTC Training Ride
– July 1: Fundraising rates increase
– Sept. 29 & 30: Pedal the Cause 2018

See all PTC events


Wear these sleek Pedal the Cause shorts with your team or custom jersey!  High quality cycling shorts produced by Primal.  Order now and shorts will be shipped out by May 15th.

Order now

Impact News

Pedal-funded researchers earn $5M grant

Ron Bose, MD, PhD and Cynthia Ma, MD, PhD recently received a notice of award for a $5 million grant from the U.S. Department of Defense (DOD) titled “Targeting HER2-Activating Mutations in ER-Positive Metastatic Breast Cancer” that will start this Spring 2018. This significant research grant to continue their research was possible due to preliminary data that was generated from two PTC-supported research projects funded in 2012 and 2016.


Featured Project

Funded in 2017

Principal Investigator:
Kristen Naegle, PhD

Goal: To uncover an important basic phenomenon that occurs within normal cell biology and gain a better understanding of the role it plays in the development of cancer cells. Findings in this study could ultimately identify new ways in which therapeutics could target and kill cancer cells.

learn more about PTC funded research >>

Gene editing CRISPR expands reach of therapeutic T cells

YOU FUNDED IT! John DiPersio, MD, PhD, leads a team with co-author Armin Ghobadi, MD developing an “off-the-shelf” CAR-T immunotherapy for hard-to-treat T cell cancers. This 2017 Pedal-funded study has used the gene-editing technology CRISPR to engineer human T cells that can attack human T cell cancers without succumbing to friendly fire. This is an important step for new treatments for hard to treat blood cancers like acute lymphoblastic leukemia and non-Hodgkin lymphoma.


Meet the #PedalFamily

Featured Riders

Top Youth Fundraisers

If we all fundraised for Pedal the Cause with the heart and gumption of these incredible kids, think about the impact on cancer research we would have! Meet our top fundraisers under 17 in 2017 – Kira, Nick, Peyton, Brinkley, Maddy (and not pictured Taylor and Griffin), pictured here at the Yellow Jersey Celebration where they were honored. Together, these 7 young riders raised an incredible $36,508 for cancer research in 2017.  We are so proud of each and every one of you!

Featured Sponsor

Edward Jones

As the Presenting Sponsor of Pedal the Cause, Edward Jones makes what we do possible. In September 2016, Edward Jones announced its commitment to the cause by donating $1 million over the next three years to Pedal the Cause. These funds are being used to offset operational expenses allowing Pedal the Cause to donate 100 percent of all participant fundraising to cancer research. In addition, Team Edward Jones is the first official member of the Platinum Impact Society, having raised over $2 million for cancer research since 2010!

Team profile

For more info on Pedal the Cause visit

Keep up with all the news and follow us on social media:




view this email in your browser

Copyright © *|CURRENT_YEAR|* *|LIST:COMPANY|*, All rights reserved.
*|IFNOT:ARCHIVE_PAGE|* *|LIST:DESCRIPTION|*Our mailing address is:

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.



    Leave a Reply

    Your email address will not be published. Required fields are marked *